Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis
Kaitlin Quinn, Joel S. Rosenblum, Casey A. Rimland et. al.

Nov 13th, 2019 - Background/Purpose: 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) is one of several imaging modalities used in the assessment of patients with large-vessel vasculitis (LVV).  Conventionally PET images are obtained 1 hour after radiotracer injection; however, delayed imaging may be more sensitive to detect vascular inflammation.    The objectives of this study were to: 1) determ...

Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Majid Zeidi, Kristen Chen, Krisha Desai et. al.

Nov 13th, 2019 - Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional skin, but plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs) also play an important role in the pathogenesis. Oral antimalarials, including hydroxychloroquine (HCQ) and quinacrine (QC)...

Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Sarah Blackstone, Daniella Schwartz, Natalia Sampaio Moura et. al.

Nov 13th, 2019 - Background/Purpose: The protein A20, encoded by TNFAIP3, represses signaling upstream of the inflammatory transcription factor nuclear factor (NF)-kB by regulating ubiquitination. Heterozygous loss-of-function mutations in TNFAIP3 cause the systemic autoinflammatory disease Haploinsufficiency of A20 (HA20) [1]. Because no FDA-approved medications directly target NF-kB signaling, current HA20 th...

Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Tianrun Cai, Fiona Cai, Kumar Dahal et. al.

Nov 13th, 2019 - Background/Purpose: Efficiently identifying eligible patients is an important component of a successful clinical trial.  Billing codes from electronic health record (EHR) data are commonly used to first screen for potential patients, followed by labor-intensive chart review to identify the eligible patients by trial criteria.  The objective of this study was to test whether a machine learning s...

Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos, Laura Coates, Laure Gossec et. al.

Nov 13th, 2019 - Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this s...

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Kim Papp, Melinda Gooderham, Akimichi Morita et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is characterized by peripheral synovitis, enthesitis, dactylitis and spondylitis, and IL-23 is involved in the pathogenesis of these conditions either directly or indirectly. Risankizumab (RZB), a potent humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, exhibited superior efficacy vs placebo via ACR responses and PASI scores in pat...

Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease
Rebecca Cleveland, Emma Astrike-Davis, Beth Jonas 1 and Leigh Callahan et. al.

Nov 13th, 2019 - Background/Purpose: In prior cross-sectional analyses of African Americans (AA) with RA, we observed that low education, income and home ownership were associated with clinical damage and patient reported outcomes (PROs) among those with mean disease duration of 7.8 years. However, when restricted to those with disease duration of < 2 years, associations with PROs remained, but were no longer o...

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
Serdal Ugurlu, Bugra Han Egeli, Bilgesu Ergezen et. al.

Nov 13th, 2019 - Background/Purpose: The main goal of Familial Mediterranean Fever (FMF) treatment is to prevent attacks and subclinical inflammation. Mainstay of treatment is colchicine; however, 5-10% of patients are unresponsive to colchicine even in maximum tolerated dosage. Anakinra has been proven to be effective in controlled trials in terms of attack frequency and subclinical inflammation in colchicine ...

Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Xanthe ME Matthijssen, Ellis Niemantsverdriet, Thomas Huizinga 2 and Annette van der Helm-van Mil et. al.

Nov 13th, 2019 - Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established to what extent other long-term outcomes have improved. Moreover, anti-citrullinated anti-bodies (ACPA)-positive and ACPA-negative disease subsets were discovered and it is unknown they have benefited equal...

A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibito...
Frances humby, Maya H. Buch, Patrick Durez et. al.

Nov 13th, 2019 - Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the potential side effects and the high cost of these drugs have highlighted the need to define predictive markers of response and to stratify patients according to therapeutic outcome. B-cells are pivotal to RA pathogenesis,...

Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Kathryn Kingsmore, Sarah Heuer, Erika Hubbard et. al.

Nov 13th, 2019 - Background/Purpose: Systemic lupus erythematosus (SLE) affects various organs and tissues, but whether pathologic processes in each organ are distinct or whether dysregulated molecular functions are found in common in all tissues is not known. We, therefore, conducted a meta-analysis of gene expression profiles in four affected SLE tissues to identify commonly dysregulated pathways. Methods: Ge...

The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Christopher Mesa, Snehaja Yadlapati 1 and Myriam Guevara, Louisiana State University Health Science Center et. al.

Nov 13th, 2019 - Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such as: Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Systemic Lupus Erythematous (SLE), Inflammatory Myositis (IM), Mixed Connective Tissue Disease (MCTD), Sjogren Syndrome and Sarcoid. Despite it being so common, treatment h...

Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biologica...
Mark Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg et. al.

Nov 13th, 2019 - Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors signaling through JAK2. Therefore, we investigated the extent of anemia, thrombocytopenia and leukopenia in patients with active RA with a prior inadequate response/intolerance to biological DMARD (bDMARD)...

Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Antonio Nino, Damon L Bass, Gina Eriksson et. al.

Nov 13th, 2019 - Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was based on the PLUTO trial (NCT01649765), which was designed to assess the safety and efficacy of BEL in children with SLE.2 Additional evidence to support the consistency of effect of BEL in children included an across-trial co...

Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang, Yu-fei Hao, Sheng-xiao Zhang et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a functional deficiency in suppressing effector T-cells in PsA, absolute quantitative status of peripheral Treg or Th17 cells is still unclear. On the other hand, recent studies have revealed that low-dose I...

Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii et. al.

Nov 13th, 2019 - Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in vascular inflammation in TAK, their target antigens remained unclear. We had constructed an expression cloning system for specific identification of cell-surface antigens, which we named SARF. The aim...

Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Spencer I Danto, Negin Shojaee, Ravi Shankar P Singh et. al.

Nov 13th, 2019 - Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of rheumatoid arthritis (RA). Toll-like receptor (TLR) stimulation activates the innate immune system, and may be involved in the pro-inflammatory response to ACPA protein complexes found in severe RA.1 Interleukin (IL) receptor-associated kinase 4 (IRAK4) is a key signal transducer downstream ...

Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
April Barnado, Lee Wheless, Leslie Crofford 2 and Joshua Denny et. al.

Nov 13th, 2019 - Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria such as renal disease. We examined if nine of these SLE risk alleles would identify autoimmune features in a population without diagnosed autoimmune diseases. Methods: We investigated subjects from BioVU, a databank that link...

The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo, George Tomlinson, Edward Keystone et. al.

Nov 13th, 2019 - Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are difficult to separate from underlying age-sex related risk of comorbid conditions (2) Long-term large sample follow-up of patients is expensive, arduous, and difficult to standardize (3) Limited methods for selecting a...

Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-ce...
Sandra van Bijnen, Maaike Boonstra, Els van den Ende et. al.

Nov 13th, 2019 - Background/Purpose: Autologous hematopoietic stemcell transplantation (HSCT) has shown to improve survival of SSc patients with poor prognosis, but is hampered by treatment related mortality (TRM). Better selection of eligible patients could improve outcomes. Objectives: 1. To evaluate event-free survival, TRM and response after HSCT in SSc and 2. To explore patient characteristics that associa...